MGNX
MGNX
NASDAQ · Biotechnology

Macrogenics Inc

$2.93
-0.25 (-7.86%)
As of Mar 29, 10:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
151.24M
Net Income
-75,485,060
Gross Margin
75.9%
Profit Margin
-49.9%
Rev Growth
-0.5%
D/E Ratio
1.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 151.24M 152.04M 19.43M 16.17M
Gross Profit 114.81M 115.42M 6.80M 5.66M
Operating Income -73,683,374 -66,668,379 4.53M 3.44M
Net Income -75,485,060 -68,298,536 4.04M 2.70M
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Rev Growth -0.5% -0.5% +14.5% +17.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 50.92M 50.92M 6.65M 6.76M
Total Equity 40.44M 40.44M 36.37M 40.78M
D/E Ratio 1.26 1.26 0.18 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -63,742,229 -60,877,769 6.14M 4.71M
Free Cash Flow 2.37M 2.40M